Salarius Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Decoy Therapeutics

11/11/2022 04:16

* Salarius Pharmaceuticals Inc  SLRX.OQ  reported a
quarterly
adjusted loss of $2.47​​ per share for the quarter ended in
September. The mean expectation of two analysts for the quarter
was for a loss of $2.55 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Salarius Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of $6.41​.
    * The mean earnings estimate of analysts had risen by
about 2.9%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Salarius Pharmaceuticals Inc shares had fallen by 62.3%
this
quarter and lost 85.1% so far this year.
    * The company reported a quarterly loss of $14.41 million.
    * Wall Street's median 12-month price target for Salarius
Pharmaceuticals Inc is $125.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 1 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
11 at 04:15 a.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -2.55          -2.47          Beat
 Jun. 30 2022      -2.62          -2.25          Beat
 Mar. 31 2022      -2.25          -3.25          Missed
 Dec. 31 2021      -2.12          -2.25          Missed